MEN1 and cancer: Importantly, a combination of highly specific and potent inhibitors of PRC2 and MEN1, which are either FDA-approved or in clinical trials to treat distinct cancer types, demonstrated remarkable efficacy in the treatment of DLBCL in xenograft study (Fig. 6).